Became law

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Record date · Nov 3, 2026

What this means

Status
Became law
What happened
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The act reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent o…
What to check next
The enacted text lists when each provision takes effect and who qualifies.
Check the original record

About this record

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The act reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Record details

Bill number
H.R. 8205
Congress
119
Introduced
2026-04-06
Sponsor
Rep. Quigley, Mike [D-IL-5]
Committees
Energy and Commerce Committee
Latest documented action
Became Public Law No: 119-138.

Documented actions

  1. Became Public Law No: 119-138.

  2. Became Public Law No: 119-138.

  3. Signed by President.

  4. Signed by President.

  5. Presented to President.

  6. Presented to President.

  7. Message on Senate action sent to the House.

  8. Passed Senate without amendment by Voice Vote. (consideration: CR S5120)

Sources and related records

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Source checked .